MX2018000073A - Agonistas de proteina de fusion btla y usos de los mismos. - Google Patents
Agonistas de proteina de fusion btla y usos de los mismos.Info
- Publication number
- MX2018000073A MX2018000073A MX2018000073A MX2018000073A MX2018000073A MX 2018000073 A MX2018000073 A MX 2018000073A MX 2018000073 A MX2018000073 A MX 2018000073A MX 2018000073 A MX2018000073 A MX 2018000073A MX 2018000073 A MX2018000073 A MX 2018000073A
- Authority
- MX
- Mexico
- Prior art keywords
- btla
- fusion protein
- present
- protein agonists
- fusion proteins
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 4
- 108020001507 fusion proteins Proteins 0.000 title abstract 4
- 101150025010 Btla gene Proteins 0.000 title 1
- 229940076376 protein agonist Drugs 0.000 title 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 abstract 2
- 229940122494 BTLA agonist Drugs 0.000 abstract 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562187105P | 2015-06-30 | 2015-06-30 | |
| PCT/US2016/040108 WO2017004213A1 (en) | 2015-06-30 | 2016-06-29 | Btla fusion protein agonists and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018000073A true MX2018000073A (es) | 2018-06-27 |
Family
ID=57609132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018000073A MX2018000073A (es) | 2015-06-30 | 2016-06-29 | Agonistas de proteina de fusion btla y usos de los mismos. |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10961297B2 (enExample) |
| EP (1) | EP3317297A4 (enExample) |
| JP (4) | JP7116285B2 (enExample) |
| KR (2) | KR20240110000A (enExample) |
| CN (2) | CN114853903A (enExample) |
| AU (3) | AU2016286108B2 (enExample) |
| BR (1) | BR112017028316A2 (enExample) |
| CA (1) | CA2990885A1 (enExample) |
| EA (1) | EA201890171A1 (enExample) |
| IL (2) | IL256383B2 (enExample) |
| MX (1) | MX2018000073A (enExample) |
| SG (1) | SG10201913567QA (enExample) |
| WO (1) | WO2017004213A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3247728T (pt) | 2015-01-20 | 2020-07-16 | Igm Biosciences Inc | Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas |
| AU2016286108B2 (en) | 2015-06-30 | 2021-03-11 | Pfizer Inc. | BTLA fusion protein agonists and uses thereof |
| GB201820554D0 (en) | 2018-12-17 | 2019-01-30 | Univ Oxford Innovation Ltd | BTLA antibodies |
| GB202008860D0 (en) | 2020-06-11 | 2020-07-29 | Univ Oxford Innovation Ltd | BTLA antibodies |
| AU2023212896A1 (en) * | 2022-01-29 | 2024-08-22 | Hifibio, Inc. | Antibody against btla and uses thereof |
| WO2023215560A1 (en) | 2022-05-05 | 2023-11-09 | Atoosa Corporation | Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp) |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6291207B1 (en) * | 1995-07-28 | 2001-09-18 | Northwestern University | Herpes virus entry receptor protein |
| TR200504220T2 (tr) | 1998-12-17 | 2007-04-24 | Biogen Idec Ma Inc. | Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem. |
| WO2007001459A2 (en) | 2004-11-15 | 2007-01-04 | Washington University | Compositions and methods for modulating lymphocyte activity |
| US8546541B2 (en) | 2002-06-20 | 2013-10-01 | Washington University | Compositions and methods for modulating lymphocyte activity |
| US20030235580A1 (en) | 2002-06-24 | 2003-12-25 | Fen Zhang | Amniotic membrane mediated delivery of bioactive molecules |
| US7153950B2 (en) | 2002-10-25 | 2006-12-26 | Genentech, Inc. | Nucleic acids encoding an immune related polypeptide |
| EP1812465B1 (en) | 2004-11-12 | 2016-09-07 | Genentech, Inc. | Novel composition and methods for the treatment of immune related diseases |
| WO2010006071A1 (en) * | 2008-07-08 | 2010-01-14 | La Jolla Institute For Allergy And Immunology | Hvem/btla, hvem/cd160 and hvem/gd cis complexes and methods of use |
| EP1833848A2 (en) | 2004-12-09 | 2007-09-19 | Lajolla Institute for Allergy and Immunology | Novel tnf receptor regulatory domain |
| US8349320B2 (en) * | 2004-12-09 | 2013-01-08 | La Jolla Institute For Allergy And Immunology | Compositions and methods for modulating responses mediated or associated with BTLA activity |
| WO2007010692A1 (ja) | 2005-07-19 | 2007-01-25 | Japan Science And Technology Agency | Ｈｖｅｍ及びｂｔｌａを標的とした炎症性腸疾患治療用医薬組成物及び治療方法 |
| MX2009005189A (es) | 2006-11-15 | 2009-06-30 | Medarex Inc | Anticuerpos humanos monoclonales para btla y metodos de uso. |
| US8318662B2 (en) | 2009-03-16 | 2012-11-27 | Korea Institute Of Radiological & Medical Sciences | Protein increasing cell infectivity of herpes simplex virus and use thereof |
| US8303952B2 (en) | 2009-06-08 | 2012-11-06 | Washington University | Methods for inducing in vivo tolerance |
| CA2769473A1 (en) * | 2009-07-31 | 2011-02-03 | N.V. Organon | Fully human antibodies to btla |
| US9982023B2 (en) | 2011-11-15 | 2018-05-29 | Sanford-Burnham Medical Research Institute | Compositions and methods for treating autoimmune and inflammatory disorders |
| JP2016530298A (ja) | 2013-09-05 | 2016-09-29 | サンフォード−バーンハム メディカル リサーチ インスティテュート | γδＴ細胞の調節 |
| KR20170134525A (ko) | 2015-04-02 | 2017-12-06 | 메모리얼 슬로안-케터링 캔서 센터 | Tnfrsf14 / hvem 단백질 및 이의 이용 방법 |
| EP3288587A4 (en) | 2015-04-29 | 2018-09-12 | Sanford-Burnham Medical Research Institute | Modulation of immune response using btla agonist antibodies |
| AU2016286108B2 (en) | 2015-06-30 | 2021-03-11 | Pfizer Inc. | BTLA fusion protein agonists and uses thereof |
| CA3013333A1 (en) | 2016-02-26 | 2017-08-31 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antibodies having specificity for btla and uses thereof |
| US12145993B2 (en) | 2016-06-08 | 2024-11-19 | Shanghai Jiao Tong University School Of Medicine | Sequence of antibody heavy chain constant region for enhancing agonistic antibody activity |
| US12281339B2 (en) | 2016-07-05 | 2025-04-22 | Polaris Group | Combination cancer immunotherapies with arginine depletion agents |
| US12447213B2 (en) | 2016-10-07 | 2025-10-21 | The Broad Institute, Inc. | Modulation of novel immune checkpoint targets |
| MY200973A (en) | 2017-04-11 | 2024-01-26 | Inhibrx Inc | Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same |
| US20200140547A1 (en) | 2017-05-26 | 2020-05-07 | The Johns Hopkins University | Multifunctional antibody-ligand traps to modulate immune tolerance |
| AU2018355487B2 (en) | 2017-10-27 | 2023-09-21 | Shanghai Yao Yuan Biotechnology Co., Ltd. | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 |
| WO2019094559A2 (en) | 2017-11-09 | 2019-05-16 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides |
| CR20200566A (es) | 2018-05-25 | 2021-02-19 | Alector Llc | Anticuerpos anti-sirpa y metodos de utilización de los mismos |
| JP7097465B2 (ja) | 2018-06-19 | 2022-07-07 | アルモ・バイオサイエンシーズ・インコーポレイテッド | キメラ抗原受容体細胞療法と併用するｉｌ－１０剤の組成およびその使用方法 |
| AU2019293589A1 (en) | 2018-06-29 | 2021-01-21 | Alector Llc | Anti-SIRP-beta1 antibodies and methods of use thereof |
| WO2020041361A1 (en) | 2018-08-20 | 2020-02-27 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides |
| CA3109563A1 (en) | 2018-09-14 | 2020-03-19 | Universite De Lausanne | Methods for modulating regulatory t cells and inhibiting tumor growth |
| EP3880711A4 (en) | 2018-11-15 | 2022-12-28 | The General Hospital Corporation | Agonistic tumor necrosis factor receptor superfamily polypeptides |
-
2016
- 2016-06-29 AU AU2016286108A patent/AU2016286108B2/en active Active
- 2016-06-29 CN CN202210348320.0A patent/CN114853903A/zh active Pending
- 2016-06-29 SG SG10201913567QA patent/SG10201913567QA/en unknown
- 2016-06-29 EP EP16818691.4A patent/EP3317297A4/en active Pending
- 2016-06-29 US US15/737,259 patent/US10961297B2/en active Active
- 2016-06-29 IL IL256383A patent/IL256383B2/en unknown
- 2016-06-29 IL IL297395A patent/IL297395B2/en unknown
- 2016-06-29 BR BR112017028316-6A patent/BR112017028316A2/en active Search and Examination
- 2016-06-29 WO PCT/US2016/040108 patent/WO2017004213A1/en not_active Ceased
- 2016-06-29 EA EA201890171A patent/EA201890171A1/ru unknown
- 2016-06-29 JP JP2017568205A patent/JP7116285B2/ja active Active
- 2016-06-29 MX MX2018000073A patent/MX2018000073A/es unknown
- 2016-06-29 CA CA2990885A patent/CA2990885A1/en active Pending
- 2016-06-29 KR KR1020247017225A patent/KR20240110000A/ko active Pending
- 2016-06-29 CN CN201680049768.5A patent/CN108026159B9/zh active Active
- 2016-06-29 KR KR1020187002960A patent/KR102669985B1/ko active Active
-
2021
- 2021-03-01 US US17/188,912 patent/US11939367B2/en active Active
- 2021-05-17 JP JP2021083133A patent/JP2021113240A/ja active Pending
- 2021-06-08 AU AU2021203768A patent/AU2021203768B2/en active Active
-
2022
- 2022-07-20 JP JP2022115473A patent/JP7559013B2/ja active Active
-
2023
- 2023-04-14 AU AU2023202302A patent/AU2023202302A1/en not_active Abandoned
- 2023-12-13 JP JP2023210069A patent/JP2024019529A/ja active Pending
-
2024
- 2024-02-15 US US18/442,988 patent/US20240247047A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020003190A (es) | Degradadores de proteinas y usos de los mismos. | |
| MX2025000260A (es) | Proteina de union al antigeno anti-steap1 | |
| EA201891709A1 (ru) | Антигенсвязывающие белки, связывающие pd-l1 | |
| MX2021002616A (es) | Anticuerpos agonistas anti receptor desencadenante expresado en celulas mieloides 2 (trem-2). | |
| AU2016286108A8 (en) | BTLA fusion protein agonists and uses thereof | |
| GT201700284A (es) | Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-cd38 e inhibidores de survivina | |
| EP4335874A3 (en) | Anti-hla-g antibodies and use thereof | |
| ZA201708265B (en) | Tigit-binding agents and uses thereof | |
| EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
| NZ753515A (en) | Methods for treatment of cancer comprising tigit-binding agents | |
| MX385915B (es) | Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos | |
| EA201792467A1 (ru) | Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены | |
| EA201790984A1 (ru) | Анти-cd79b антитела и способы их применения | |
| EA201791139A1 (ru) | Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены | |
| NZ725568A (en) | Modified j-chain | |
| MX2017016169A (es) | Anticuerpos anti-her2 y metodos de uso. | |
| PH12020551710A1 (en) | Anti-hla-g antibodies and use thereof | |
| MX2017003478A (es) | Anticuerpos anti-fgfr2/3 y metodos para su uso. | |
| AU2016219350A8 (en) | Humanized anti-MUC1* antibodies | |
| EP3543335A3 (en) | Soluble intein fusion proteins and methods for purifying biomolecules | |
| MY191944A (en) | Binding proteins and methods of use thereof | |
| MX2019010846A (es) | Polipeptidos de il-22 y proteinas de fusion de il-22 fc y metodos de uso. | |
| EP3705494A3 (en) | Antibodies against frizzled proteins and methods of use thereof | |
| SA519410534B1 (ar) | أجسام مضادة لعامل مساعد لموهن الخلايا الليمفاوية البائية والتائية واستخداماتها | |
| EA201792220A1 (ru) | Опосредуемая антителом нейтрализация вируса чикунгунья |